Technical Analysis for RENE - Reneuron Group Plc

Grade Last Price % Change Price Change
F 3.38 -2.17% -0.08
RENE closed down 2.17 percent on Monday, February 5, 2024, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -2.17%
Stochastic Reached Oversold Weakness -2.17%
Wide Bands Range Expansion -2.17%
Oversold Stochastic Weakness -2.17%
New 52 Week Closing Low Bearish -0.74%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reneuron Group Plc Description

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Medicine Life Sciences Cancer Branches Of Biology Clinic Earl Biology Emerging Technologies Therapy Clinical Trial Cell Therapy Therapies Stroke Stem Cells Cell Biology Disability Nanomedicine

Is RENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.5
52 Week Low 3.275
Average Volume 410,126
200-Day Moving Average 6.68
50-Day Moving Average 3.97
20-Day Moving Average 4.03
10-Day Moving Average 3.68
Average True Range 0.31
RSI (14) 36.71
ADX 27.43
+DI 13.56
-DI 25.61
Chandelier Exit (Long, 3 ATRs) 4.69
Chandelier Exit (Short, 3 ATRs) 4.21
Upper Bollinger Bands 4.87
Lower Bollinger Band 3.19
Percent B (%b) 0.11
BandWidth 41.53
MACD Line -0.18
MACD Signal Line -0.10
MACD Histogram -0.0787
Fundamentals Value
Market Cap 1.93 Million
Num Shares 57.1 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -37.50
Price-to-Sales 7.75
Price-to-Book 0.80
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.67
Resistance 3 (R3) 3.67 3.57 3.62
Resistance 2 (R2) 3.57 3.49 3.57 3.60
Resistance 1 (R1) 3.47 3.45 3.42 3.47 3.59
Pivot Point 3.37 3.37 3.35 3.37 3.37
Support 1 (S1) 3.28 3.30 3.23 3.28 3.16
Support 2 (S2) 3.18 3.25 3.18 3.15
Support 3 (S3) 3.08 3.18 3.13
Support 4 (S4) 3.08